



May 29, 2026

Company name: ROHTO Pharmaceutical Co., Ltd.

Representative: Hidetoshi Segi,

President and Representative Director

(Code: 4527 TSE Prime)

Contact:

Masaya Saito, Vice President and CFO

(TEL: 06-6758-8223)

Completion of Share Acquisition of Thann Oryza Co., Ltd.

Rohto Pharmaceutical Co., Ltd. (Head Office: Ikuno-ku, Osaka; President & CEO: Hidetoshi Segi) announced the acquisition of shares in Thann Oryza Co., Ltd. (making it a subsidiary) on January 7, 2026. Today, on May 29, 2026, we announce that we have completed the acquisition of shares in Thann Oryza Co., Ltd. and making it a subsidiary, with a delay for a reason of extra time required for registration and approval with relevant authorities and for the issuance of shares.

1. Completion Date of Share Acquisition: May 29, 2026

2. Future Outlook

We are currently reviewing the impact of this transaction on our consolidated financial results. We will promptly disclose any matters in case further announcement is required.